# A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

> **NCT02313077** · PHASE1 · COMPLETED · sponsor: **Crucell Holland BV** · enrollment: 87 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** MVA-BN-filo
- **BIOLOGICAL:** Ad26. ZEBOV
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02313077
- **Lead sponsor:** Crucell Holland BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-17
- **Primary completion:** 2015-04-17
- **Final completion:** 2016-03-15
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2017-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02313077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02313077, "A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02313077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*